(Q33899122)

29 July 2017

1 reference

title

Thalidomide: current and potential clinical applications (English)

1 reference

29 July 2017

0 references

Calabrese L

1

1 reference

PubMed ID

10781782

29 July 2017

Fleischer AB

series ordinal

2

1 reference

PubMed ID

10781782

29 July 2017

language of work or name

English

0 references

publication date

1 April 2000

1 reference

American Journal of Medicine

29 July 2017

1 reference

29 July 2017

108

1 reference

29 July 2017

487-495

1 reference

29 July 2017

6

1 reference

Inhibition of PMN leukocytes chemotaxis by thalidomide

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

Studies on the anti-inflammatory properties of thalidomide: effects on polymorphonuclear leukocytes and monocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

Thalidomide as an anti-TNF-alpha inhibitor: implications for clinical use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

The Influence of Thalidomide on the Clinical and Immunologic Manifestation of Erythema Nodosum Leprosum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

Role of tumor necrosis factor-alpha in disease states and inflammation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

Thalidomide increases the synthesis of IL-2 in cultures of human mononuclear cells stimulated with Concanavalin-A, Staphylococcal enterotoxin A, and purified protein derivative

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

Thalidomide is an inhibitor of angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

THALIDOMIDE IN THE TREATMENT OF LEPRA REACTIONS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

Thalidomide in the Treatment of Recurrent, Necrotic, and Giant Mucocutaneous Aphthae and Aphthosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

Thalidomide treatment of recurrent necrotic giant mucocutaneous aphthae and aphthosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

Significant response of oral aphthosis to thalidomide treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

Thalidomide and recurrent aphthous stomatitis: a follow-up study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

Thalidomide effects in Behçet's syndrome and pustular vasculitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

Thalidomide in the treatment of Behçet's syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

Thalidomide for systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

Sequential combined therapy with thalidomide and narrow-band (TL01) UVB in the treatment of prurigo nodularis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

Recurrent aphthous ulcer in patient infected with human immunodeficiency virus: successful treatment with thalidomide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

Use of thalidomide in treatment and maintenance of idiopathic esophageal ulcers in HIV+ individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

Prolonged thalidomide therapy for human immunodeficiency virus-associated recurrent severe esophageal and oral aphthous ulcers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

Thalidomide as treatment of refractory aphthous ulceration related to human immunodeficiency virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

Thalidomide to treat esophageal ulcer in AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

A prospective trial of thalidomide for the treatment of HIV-associated idiopathic esophageal ulcers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

Metabolic disturbances and wasting in the acquired immunodeficiency syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

Faecal tumour necrosis factor-alpha in individuals with HIV-related diarrhoea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

The treatment of microsporidial diarrhoea with thalidomide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

Thalidomide inhibits the replication of human immunodeficiency virus type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

Thalidomide and thalidomide analogs reduce HIV type 1 replication in human macrophages in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

Thalidomide for graft-versus-host disease after bone marrow transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

Successful treatment with thalidomide of acute graft-versus-host disease after bone-marrow transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

Thalidomide treatment for chronic graft-versus-host disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

Thalidomide for the treatment of chronic graft-versus-host disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

An open study of pentoxyfylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

CLINICAL EXPERIENCES WITH THALIDOMIDE IN PATIENTS WITH CANCER

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

THALIDOMIDE (N-PHTHALOYLGLUTAMIMIDE) IN THE TREATMENT OF ADVANCED CANCER.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

Regression of AIDS-related Kaposi's sarcoma during therapy with thalidomide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

The saga of thalidomide. Neuropathy to embryopathy, with case reports of congenital anomalies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

Thalidomide neuropathy: a clinical electrophysiological, and histological follow-up study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behçet's disease: use of neurophysiological studies to detect thalidomide neuropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

Thalidomide Therapy for Inflammatory Dermatoses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

Effect of thalidomide on the inflammatory response in cerebrospinal fluid in experimental bacterial meningitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

A combination of thalidomide plus antibiotics protects rabbits from mycobacterial meningitis-associated death.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

Thalidomide inhibits TNF response and increases survival following endotoxin injection in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

Thalidomide in the treatment of erythema nodosum leprosum. With a note on selected laboratory abnormalities in erythema nodosum leprosum.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900408-8

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9343(99)00408-8

1 reference

29 July 2017

1 reference

PubMed ID

10781782